Related references
Note: Only part of the references are listed.Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells
Amalia Azzariti et al.
BIOCHEMICAL PHARMACOLOGY (2008)
Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature:: Implications for clinical imaging
Christian R. Schnell et al.
CANCER RESEARCH (2008)
NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
Violeta Serra et al.
CANCER RESEARCH (2008)
Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer
Philipp C. Manegold et al.
CLINICAL CANCER RESEARCH (2008)
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
Sauveur-Michel Maira et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
An in vivo platform for translational drug development in pancreatic cancer
Belen Rubio-Viqueira et al.
CLINICAL CANCER RESEARCH (2006)
Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma
Krishdeep S. Chadha et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Phosphoinositide 3-kinase: From viral oncoprotein to drug target
PK Vogt et al.
VIROLOGY (2006)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
Pancreatic cancer cell radiation survival and prenyltransferase inhibition: The role of K-ras
TB Brunner et al.
CANCER RESEARCH (2005)
Recent advances in the protein kinase B signaling pathway
JR Woodgett
CURRENT OPINION IN CELL BIOLOGY (2005)
Inhibition of integrin-linked kinase by QLT0254 inhibits Akt-dependent pathways and is growth inhibitory in orthotopic primary pancreatic cancer xenografts
CYF Yau et al.
CANCER RESEARCH (2005)
Oncogenic K-ras drives cell cycle progression and phenotypic conversion of primary pancreatic duct epithelial cells
C Agbunag et al.
CANCER RESEARCH (2004)
The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells
T Asano et al.
ONCOGENE (2004)
Autocrine-mediated ErbB-2 kinase activation of STAT3 is required for growth factor independence of pancreatic cancer cell lines
D DeArmond et al.
ONCOGENE (2003)
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis
SP Thayer et al.
NATURE (2003)
Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death
A Arlt et al.
ONCOGENE (2003)
Pancreatic cancer biology and genetics
N Bardeesy et al.
NATURE REVIEWS CANCER (2002)
Share Paper
